Entasis Therapeutics is being acquired by Innoviva in a deal that brings an FDA-ready antibiotic developed to address drug-resistant strains of a bacterium that infects critically ill, immunocompromised patients. Innoviva has been steadily building up its stake in Entasis, an AstraZeneca spinout, over the past two years.
AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed from Pfizer, to a pivotal test in a rare and potentially fatal lung infection caused by mycobacteria.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A report from ECRI Institute outlined the 10 biggest patient safety concerns, and diagnostic errors and improper management of test results in EHRs topped the list.
Researchers have found a fertile source for new antibiotics: Vaginal bacteria. It’s a Darwinian world down there, with “good,” antibiotic-producing bacteria present to combat more malevolent microcritters like MRSA. So when plumbing the depths of the microbiome, University of California, San Francisco researchers essentially discovered a new antibiotic. Their findings were published Sept. 11 in Cell. Interestingly, the news stretches […]
North Carolina antibiotics maker Cempra has received a $10 million milestone payment from a Japanese drugmaker – indicative of the country’s need for a next-gen antibiotic. Toyama Pharmaceutical, a subsidiary of Fujifilm Holdings, owns exclusive rights to develop and commercialize Cempra’s new antibiotic, solithromycin, in Japan for respiratory tract infections like pneumonia. Though U.S. usage is number […]